The Positive Side Effects of Mounjaro — What Clinical Trials Actually Found

Metabolic improvements observed in SURMOUNT-1 and what they mean

The SURMOUNT-1 trial, published in the New England Journal of Medicine, tracked 2,539 adults with obesity over 72 weeks. Participants taking the 15mg dose lost an average of around 20–21% of their body weight, but the secondary endpoints tell a story that is often overlooked. Reductions in waist circumference, systolic blood pressure, fasting blood glucose, triglycerides and LDL cholesterol were all recorded. HDL cholesterol, the protective kind, rose on average.

These changes are not simply a downstream consequence of eating less. Tirzepatide acts on both GIP and GLP-1 receptors, which means it influences insulin secretion, glucagon suppression and fat-cell metabolism more directly than weight reduction alone would explain. The clinical significance of that dual action is still being studied, but it is part of why NICE's appraisal of tirzepatide (TA1026) judged the medicine cost-effective for people with a weight-related comorbidity rather than high BMI alone.

For a fuller picture of how Mounjaro's side-effect profile breaks down, including the common gastrointestinal effects that accompany these benefits, our dedicated side-effects page covers both in detail. On this page the focus is on what the evidence specifically found on the positive side.

Blood pressure, cholesterol and sleep: secondary findings worth knowing about

Outside the headline weight figures, trial participants on tirzepatide showed meaningful reductions in blood pressure, an effect seen early in treatment and maintained. For people whose weight had been contributing to hypertension, this is clinically significant: even modest reductions in systolic pressure reduce cardiovascular risk over time.

Cholesterol profiles improved in a pattern consistent with reduced fat mass and improved insulin sensitivity: lower triglycerides, lower LDL, higher HDL. In participants with obstructive sleep apnoea (one of the qualifying conditions for private prescription at BMI 27 or above) improvements in sleep apnoea severity scores were also documented, a benefit that carries its own quality-of-life weight.

Physical functioning scores improved too. Participants reported better mobility and greater ease with everyday activity as weight fell, changes that compound over time. The NHS tirzepatide medicines page notes these wider effects in its patient-level information, and it is worth reading the NHS's summary of tirzepatide alongside your prescriber's guidance. If you are curious about what happens when these effects are not as strong as expected, the page on minimal Mounjaro response covers that question directly.

When to get medical help, and the effects that need prompt attention

A balanced picture of Mounjaro's positive side effects cannot stand without its counterpart. The same gastrointestinal slowing that reduces appetite can, in a small number of people, contribute to more serious problems. The MHRA's January 2026 Drug Safety Update identified acute pancreatitis as an infrequent but potentially serious risk: seek urgent medical attention for severe, persistent stomach pain that radiates towards the back, with or without vomiting.

Other signs that need prompt review include gallbladder symptoms, such as sudden, intense pain in the upper right abdomen that may indicate a problem worth understanding before it develops, signs of significant dehydration if vomiting or diarrhoea is prolonged, allergic reactions such as severe rash or difficulty breathing, and any new or worsening low mood or thoughts of self-harm. The full list of warning signs is in the Patient Information Leaflet that comes with your pen, reading it is worth the ten minutes.

Suspected adverse effects can be reported directly to the MHRA via the Yellow Card scheme. You do not need to be certain something is connected; reporting a suspicion is the point. Our guide to Mounjaro's adverse effects covers these topics in more depth, and our prescribers discuss both risks and expected benefits with you as part of the consultation process.

How the positive effects relate to your eligibility and what happens at consultation

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability; a prescriber looks at the whole clinical picture, including whether the metabolic benefits are likely to be meaningful for your specific health profile.

At nume, a GPhC-registered prescriber (not an automated system) reviews your consultation the same day. That review covers not just whether you qualify, but whether Mounjaro is the right medicine for you given your existing conditions and any medications, and our overview of the five most commonly reported Mounjaro side effects is a useful starting point before that conversation. Some people keep their Mounjaro pen on the fridge door next to everyday staples, which is perfectly fine for short-term storage; the Patient Information Leaflet sets out the exact room-temperature window, and following it matters for the medicine to work as the trials showed.

If you'd like to explore the treatment options available through our weight-loss service, or to understand what private Mounjaro treatment costs through a regulated UK pharmacy, both pages give a clear, honest picture. To discuss whether Mounjaro's full profile (positive effects included) is right for you, check your eligibility with our prescribers.